DEEP BRAIN STIMULATION DEVICES MARKET ANALYSIS

Deep brain stimulation (DBS) device, often described as brain pacemaker, aids in alleviating symptoms of Parkinson’s disease (PD). The device is implanted at one of the three U.S. Food and Drug Administration (FDA) approved brain sites to block the electrical signals from these sites to the brain. The three U.S. FDA approved targeted brain sites are ventrointermedialis (VIM) nucleus of the thalamus, subthalamic nucleus (STN), and globus pallidus pars interna (GPi). DBS surgery is performed on patients suffering from PD for at least four years and are on medications albeit with motor complications.

DBS is the most preferred option although, there are other surgical options such as Thalamotomy and Pallidotomy, as it does not involve tissue destruction and is a reversible surgical treatment.

Global deep brain stimulation device market size was valued at US$ 1,188.9 million in 2022 and is expected to witness a CAGR of 9.8% over the forecast period (2022 – 2030).

Figure 1. Global Deep Brain Stimulation Device Market Share (%), by Application, 2022

To learn more about this report, request sample copy

High prevalence of diseases such as Parkinson’s disease and epilepsy is expected to fuel the global deep brain stimulation devices market growth

Increasing prevalence of PD is expected to boost demand for DBS devices. For instance, according to the Parkinson’s disease Foundation, as of 2022, over 10 million people are suffering from Parkinson’s disease, worldwide. The findings published by the organization demonstrated that incidence rate of PD increases with age and only 4% of people were diagnosed with PD before the age of 50 years. According to the same source, in 2021, the incidence rate of PD in the U.S is as high as 60,000, annually.

Increasing prevalence of epilepsy is also expected to boost demand for DBS devices. For instance, according to the data published by the World Health Organization, on February 9, 2022, around 50 million people worldwide have epilepsy, making it one of the most common neurological diseases globally. Nearly 80% of people with epilepsy live in low and middle-income countries like India, Kenya and Bangladesh.

Therefore, high prevalence of PD and epilepsy worldwide is expected to drive the global deep brain stimulation devices market growth over the forecast period.

Figure 2. Global Deep Brain Stimulation Device Market Share (%), by Region, 2022

To learn more about this report, request sample copy

Frequent approval and launch of novel devices is expected to fuel the global deep brain stimulation devices market growth

Key players in the market are focused on approval and launch of novel DBS devices to expand their product portfolio, which is expected to boost the market growth. For instance, in January 2019, Boston Scientific Corporation launched two new DBS devices namely the Vercise Primary Cell (PC) and Vercise Gevia Deep Brain Stimulation (DBS) systems.

Furthermore, key players in the market are focused on launching upgraded versions of their already approved DBS devices in the market. For instance, on May 24, 2022, OH – Great Lakes NeuroTechnologies (GLNT), diagnostic and therapy systems, announced that it has launched a multicenter research study to collect data to enhance its Kinesia motor assessment technology specifically for identifying when a patient with Parkinson’s disease (PD) is ready to consider an advanced therapy such as deep brain stimulation (DBS) or an implantable drug pump and recognize when a patient needs a therapy adjustment. The therapy is recommended when oral medication no longer provides sufficient relief of motor symptoms like rigidity, slowness of movement, fall and dizziness, freezing, muscle cramps and dystonia.

Global Deep Brain Stimulation Devices Market– Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization had declared it a public health emergency on January 30, 2020.

The sudden outbreak of COVID-19 has bought the world to a standstill. The whole world is fighting this pandemic with increased burden on hospitals and healthcare professionals. Manufacturers have found it difficult to serve their surgeon customers since some hospitals have restricted access to their facilities or changed access regulations. For instance, in December 2020, according to the report of National Center of Biotechnology Information, lockdown restriction measures were associated with subjective worsening of motor and psychiatric symptoms like significant tiredness, low energy or problems sleeping in Parkinson Disease and dystonic patients treated with DBS, and they may have exacerbated the burden of neurological disease and increased the chronic stress related to the DBS management.

Global Deep Brain Stimulation Devices Market: Key Developments

• Increasing adoption of new technologies in the hospitals is expected to drive the growth of global deep brain stimulation devices market, according to press released by MGM Healthcare in February 2020, the MGM Healthcare, Tamil Nadu, performed first Deep Brain Stimulation (DBS) surgery for Obsessive Compulsive Neurosis or OCD, a mental illness.
• Moreover, increasing number of prevalence of Parkinson’s Disease is expected to drive the growth of global deep brain stimulation devices market, according to a study report published by Parkinson’s Disease Society of the United Kingdom in 2022, it was estimated that the rate of prevalence in 2017, was 1-2 people in every 100,000 aged 20-29 and 4 or 5 people in every 100,000 aged 30-39. Prevalence increased with age with the prevalence for those aged 80-84 being 1,696 per 100,000 people which is equivalent to around 1.7% of this age-group in the U.K.
• For instance, in January 2021, BrainsWay Ltd., a global advanced non-invasive treatment of brain disorders, announced an exclusive distribution agreement with Gaelan Medical Trade LLC, healthcare company with extensive distribution channels in the U.A.E. The agreement establishes a multiyear framework whereby BrainsWay will supply its patented, revolutionary Deep Transcranial Magnetic Stimulation (Deep TMS) system, which is currently marketed in various markets for brain disorders including major depressive disorder (MDD) and obsessive-compulsive disorder (OCD), to now be marketed and sold throughout the U.A.E.

Global Deep Brain Stimulation Devices Market Restraints

One of the key factors hampering the growth of global deep brain stimulation device market is the associated risks involved with deep brain stimulation procedures like misplacement of leads and bleeding in the brain. For instance, the fundamental power source and configurable component of DBS devices is the implanted pulse generator (IPG). The use of deep brain stimulation devices for Parkinson's disease is anticipated to be constrained by the danger of infections brought on by IPG. Therefore, healthcare stakeholders should raise knowledge about the use of tack-up sutures and lower profile devices, as well as antimicrobial impregnation and co-administration.

 Key Players

Key players operating in the global deep brain stimulation devices market include Boston Scientific Corporation, Medtronic, Inc., St. Jude Medical, Inc. (Abbott Laboratories), Cyberonics, Inc., Neuronetics, and Aleva Neurotherapeutics SA.